Cellebrite DI (NASDAQ:CLBT) Trading Down 6.2% Following Analyst Downgrade

Cellebrite DI Ltd. (NASDAQ:CLBT)’s share price was down 6.2% on Monday after Weiss Ratings downgraded the stock from a hold (c-) rating to a sell (d+) rating. The company traded as low as $10.95 and last traded at $10.45. Approximately 428,923 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 2,130,758 shares. The stock had previously closed at $11.14.

CLBT has been the subject of several other reports. Lake Street Capital reduced their price target on Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday. JPMorgan Chase & Co. cut their target price on Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a research note on Friday. Needham & Company LLC reduced their target price on Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday. Finally, DA Davidson decreased their price target on Cellebrite DI from $22.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and an average price target of $16.70.

Insider Buying and Selling at Cellebrite DI

In other Cellebrite DI news, CFO David Barter sold 41,734 shares of the firm’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer directly owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This trade represents a 11.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Thomas E. Hogan sold 139,713 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the transaction, the chief executive officer owned 790,548 shares of the company’s stock, valued at $12,166,533.72. This trade represents a 15.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 285,276 shares of company stock valued at $4,470,330. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Cellebrite DI

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its stake in Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of Cellebrite DI in the 3rd quarter valued at about $40,000. CWM LLC boosted its position in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after acquiring an additional 889 shares during the last quarter. Elevation Wealth Partners LLC bought a new stake in shares of Cellebrite DI during the 2nd quarter valued at about $44,000. Finally, First Horizon Corp boosted its position in shares of Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after acquiring an additional 2,337 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

The company has a market cap of $2.59 billion, a PE ratio of 47.22, a price-to-earnings-growth ratio of 1.38 and a beta of 1.18. The company has a fifty day moving average price of $14.47 and a 200 day moving average price of $14.01.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.